Genmab upgraded by Guggenheim with a new price target
$GMAB
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim upgraded Genmab from Neutral to Buy and set a new price target of $43.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/23/2025 | $43.00 | Neutral → Buy | Guggenheim |
| 4/1/2025 | Mkt Perform → Underperform | Bernstein | |
| 3/11/2025 | Mkt Perform → Outperform | William Blair | |
| 2/13/2025 | $27.00 | Market Perform → Outperform | Leerink Partners |
| 10/8/2024 | Buy | Redburn Atlantic | |
| 9/4/2024 | $31.00 | Equal-Weight | Morgan Stanley |
| 8/20/2024 | Overweight → Neutral | JP Morgan | |
| 7/15/2024 | Sector Perform → Outperform | RBC Capital Mkts |
Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), regardless of FRα expression A Phase 3 trial in endometrial cancer is underway U.S. FDA recently granted Breakthrough Therapy Designation to Rina-S for advanced endometrial cancer Genmab A/S (NASDAQ:GMAB) announced today updated data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, TOPO1-inhibitor antibody-drug conjugate (ADC). The study showed that at a median study follow-up of one year,
Company Announcement Net sales of DARZALEX® in the third quarter of 2025 totaled USD 3,672 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; October 14, 2025 – Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,672 million in the third quarter of 2025. Net trade sales were USD 2,088 million in the U.S. and USD 1,584 million in the rest of the world. Genmab receives royalties on the
Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-st
Guggenheim upgraded Genmab from Neutral to Buy and set a new price target of $43.00
Bernstein downgraded Genmab from Mkt Perform to Underperform
William Blair upgraded Genmab from Mkt Perform to Outperform
6-K - GENMAB A/S (0001434265) (Filer)
6-K - GENMAB A/S (0001434265) (Filer)
6-K - GENMAB A/S (0001434265) (Filer)
ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria
Company Announcement COPENHAGEN, Denmark; February 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that Tahamtan Ahmadi, M.D., Ph.D., has been appointed to the newly created position of Executive Vice President and Chief Medical Officer, Head of Experimental Medicines effective March 1, 2021. Dr. Tahi Ahmadi joined Genmab in 2017 and previously served as Genmab’s Senior Vice President, Head of Oncology. In this new role, Dr. Ahmadi will lead research, discovery, regulatory and medical activities. He joins the Executive Management Team of Chief Executive Officer Dr. Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, and Chief Opera
Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-st
Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, 2025, – Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus,
Company Announcement COPENHAGEN, Denmark; August 12, 2025 – Genmab A/S (NASDAQ:GMAB) will increase its share capital by 4,563 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,580 shares at DKK 1,025.00,1,874 shares at DKK 1,050.00, and109 shares at DKK 1,161.00. Proceeds to the company are approximately DKK 4.7 million. The increase corresponds to approximately 0.01% of the company's share capital. The new shares are ordinary shares without any special rights and are freely tra
SC 13G/A - GENMAB A/S (0001434265) (Subject)
SC 13G/A - GENMAB A/S (0001434265) (Subject)
SC 13G - GENMAB A/S (0001434265) (Subject)